BioSpace News Archive

Alcresta Therapeutics, Inc. today announced a series of commercial milestone achievements.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of the XARELTO® vascular dose in reducing severe vascular events in patients with PAD after lower-extremity revascularization, a procedure that restores blood flow to the legs.

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced financial results for the year ended December 31, 2021.

McKesson Corporation announced that the McKesson board of directors has elected W. Roy Dunbar as director and member of the Audit and Governance Committees, effective April 1, 2022.

Pressure BioSciences, Inc. today announced that the Company will host a teleconference to discuss its Fourth Quarter and Fiscal Year 2021 financial results and to provide a business update.

Fulcrum Therapeutics, Inc. today announced multiple oral and poster presentations on losmapimod for facioscapulohumeral muscular dystrophy (FSHD) at the American Academy of Neurology’s Annual Meeting, taking place April 2-7 in Seattle, WA.

BioCorRx Inc. today provided a year-end business update for 2021 and reported on recent corporate developments.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced results from the Phase 3 KINECT-HD study, which demonstrated once-daily administration of valbenazine was associated with significant improvement in chorea associated with Huntington disease (HD) compared with placebo.

The campaign launches alongside two new public services announcements, encouraging everyone to join the urgent mission to create a future without Parkinson’s disease.

Zymeworks Inc., a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, announced that management will participate in upcoming investor conferences: Wells Fargo 2022 Biotech Forum.